Cite
APA Citation
Moreno, V., Gaudy-Marqueste, C., Wermke, M., Italiano, A., Romano, E., Marabelle, A., Connors, E., Zhou, H., Dobrenkov, K., Chartash, E., Calvo, E., & Aller, E. C. (n.d.). 794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors. Journal for immunotherapy of cancer, 8, A474–A475. http://access.bl.uk/ark:/81055/vdc_100144728682.0x000006